Distribution of alleles, genotypes and haplotypes of the CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) genes in the Malian population

Implication for pharmacogenetics

Yaya Kassogue, MD, PhD, Brehima Diakite, MD, PhD, Oumar Kassogue, PharmD, Issa Konate, MD, Kadidiatou Tamboura, MD, Zoumana Diarra, MD, Mamoudou Maiga, MD, PhDb, Hind Dehbi, MD, Seydou Doumbia, MD, PhD, Guimogo Dolo, PhD

Abstract

Cytochrome P450 enzymes play a central role in the phase I biotransformation process of a wide range of compounds, including xenobiotics, drugs, hormones and vitamins. It is noteworthy that these enzymes are highly polymorphic and, depending on the genetic makeup, an individual may have impaired enzymatic activity. Therefore, the identification of genetic variants in these genes could facilitate the implementation of pharmacogenetic studies and genetic predisposition to multifactorial diseases. We have established the frequencies of CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) alleles and genotypes in 209 healthy Malian subjects using TaqMan drug metabolism genotyping assays for allelic discrimination. Allele frequencies were 37% for CYP2B6 rs3745274; 38% for CYP2B6 rs2279343; and 75% for CYP3A4 rs2740574 respectively. Overall, the frequencies observed in Mali are statistically comparable to those reported across Africa except North Africa. The major haplotypes in CYP2B6 rs3745274 and CYP2B6 rs2279343 were represented by GA (60.24%) followed by TG (35.36%). We noted a strong linkage disequilibrium between CYP2B6 rs3745274 and CYP2B6 rs2279343 with D’ = 0.91 and r² = 0.8. The frequencies of the genotypic combinations were 43.5% (GT/AG), 37.3% (GG/AA) and 11.5% (TT/GG) in the combination of CYP2B6-rs3745274 and CYP2B6-rs2279343; 26.8% (GT/CC), 25.4%, (GT/CT), 17.2% and GG/CT in the combination CYP2B6-rs3745274-CYP3A4-rs2740574; 26.8% (AG/CC), 23.9% (AA/CC), 19.1% (AG/CT), and 11% (AA/CT) in the combination CYP2B6-rs2279343-CYP3A4-rs2740574, respectively. The most common triple genotype was GT/AG/CC with 24.9%, followed by GG/AA/CC with 23.9%, GT/AG/CT with 16.7%, and GG/AA/CT with 10%. Our results provide new insights into the distribution of these pharmacogenetically relevant genes in the Malian population. Moreover, these data will be useful for studies of individual genetic variability to drugs and genetic predisposition to diseases.

Abbreviations: CE = Ethic Committee, CYP450 = Cytochrome P450, EDCTP = European and Developing Countries Clinical Trials Partnership, ETA = Ethylenediaminetetraacetic acid, FAPH = Faculty of Pharmacy, FMOS = Faculty of Medicine and Odontostomatologie, ICER = International Center of Excellence in Research, SNP = Single Nucleotide Polymorphism, SPATOMA = Study of pharmacogenetics of ARVs treatment outcomes in Mali, West Africa, TMA = Training Mobility Action, UCRC = University Clinical Research Center, USTTB = University of Sciences, Techniques and Technologies of Bamako.

Keywords: CYP2B6 (A > G) rs2279343, CYP2B6 (G > T) rs3745274, CYP3A4 (C > T) rs2740574, genotype, Mali
1. Introduction
Cytochrome P450 (CYP450) enzymes are a superfamily of hemoproteins involved in phase I of the metabolism drugs and many other xenobiotics, thus playing a vital role in protecting the body against toxic derivatives from harmful compounds. In fact, the biotransformation reactions carried out by CYP450 allow the body to protect itself against the occurrence of cancers and the toxic effects of drugs or even other endogenous or exogenous substances such as hormones and vitamins, thus contributing substantially to the body's homeostasis. In mammals, CYP450 is expressed with a much higher concentration in the liver, but also to a lesser extend in the small intestine, lung and the kidney. It has been reported that 90% of the metabolism process are driven by CYP450 1A-4 families. In addition, CYP450 is known to be highly polymorphic and, depending on genetic background, these enzymes can affect the pharmacokinetics and pharmacodynamics of drugs at the individual level, thus explaining interindividual genetic differences in response to drugs.

2. Materials and methods

2.1. Study participants
The study protocol was approved by the Ethics Committee of the Faculty of Medicine and Odontostomatologie (FMOS)/Faculty of Pharmacy (FAPH), University of Sciences, Techniques and Technologies of Bamako (USTTB) under the number 2018/113/CE/FMPOS. All participants received a detailed explanation of the study protocol before agreeing to sign the informed consent. For molecular biological purposes, five milliliters of peripheral venous blood were collected from each participant in a tube containing EDTA as an anticoagulant and stored at -20°C at the laboratory of the International Center of Excellence in Research-Mali (ICER, Mali). In sum, we recruited 209 healthy and unrelated subjects, including 120 female and 89 male from August 2018 to January 2019. The study participants recruited at the Department of Infectious and Tropical Diseases, University Hospital Center of Point G.

2.2. CYP2B6 (rs3745274, rs2279343) and CYP3A4 (rs2740574) genotyping
Genomic DNA was isolated from white blood cells using the Gentra Puregene Blood Kit according to the manufacturer's instructions. Reagents for TaqMan drug metabolism genotyping assays for allelic discrimination (Applied Biosystems Genotyping Assays) were used to establish the genetic profile of study participants. The following assays identification numbers were used: C_7817766_60 rs3745274 for CYP2B6, C_1837671_50 rs2740574 for CYP3A4 rs2740574, a custom designed TaqMan assay was performed for CYP2B6 rs2279343. The 7500 Fast Real-Time PCR System (Applied Biosystems) was used to genotype the different SNPs. PCR mixture consisted of a 5 μl TaqMan master mix (2X), 0.5 μl TaqMan drug metabolism genotyping assays mix (20X), and 1 μl of DNA completed to 10 μl with nuclease free water. The PCR run method was as follows: an initial step at 60°C for 30s, hold stage at 95°C for 10min followed by 40 cycles: step 1 at 95°C for 15 s and step 2 at 60°C for 1 min supplemented by a read stage at 60°C for 30s.

2.3. Statistical analysis
The SPSS version 16 statistical package (SPSS Inc., Chicago, IL, USA) was used to assess the frequencies of CYP2B6 rs3745274, rs2279343) and CYP3A4 (rs2740574) in our population. The chi-square (X²) test was used to check whether the distribution of alleles is in Hardy–Weinberg equilibrium or not. We compared the frequencies observed in Mali with the frequencies of other populations with the same test. Analysis of pairwise linkage disequilibrium between SNPs in CYP2B6 was performed using SNPsstats. A P-value less than .05 was considered statistically significant.

3. Results
In the present work, we established the allele and genotypic frequencies of the CYP2B6 and CYP3A4 genes in 209 healthy Malian subjects using the TaqMan genotyping method. Our study group was composed of 57.4% women and 42.6% men with a mean age of 30.5 ± 11.9 years (range 18–78 years). Table 1 displays the distribution of the three SNPs in the Malian population, The profiles of the genotypes observed in the
CYP2B6 gene were 40% (GG), 46% (GT), and 14% (TT) in exon 4; 38% (AA), 48% (AG), and 14% (GG) in exon 5, respectively. In CYP3A4 gene, the genotypes observed were 57% for CC, 35% for CT and 7% for TT. The minor allele frequencies were 37%, 38%, and 25% for CYP2B6-rs3745274, CYP2B6-rs2279343 and CYP3A4-rs2740574, respectively. We found no deviations from the Hardy–Weinberg equilibrium in the SNPs examined. The distribution of CYP2B6, and CYP3A4 was statistically comparable between males and females. Major haplotypes identified from exons 4 and 5 in the CYP2B6 gene were observed in subjects carrying GA (60.24%) and TG (35.36%), while minor haplotypes were found in individuals harboring GG with 2.44% or TA with 1.96% (Fig. 1). A strong linkage disequilibrium was observed between the two SNPs in CYP2B6 with D’=0.91 and r²=0.9. The frequencies of the different genotype combinations are summarized in Figure 2. When analyzing the combinations of double genotype we noted in genotypes 1 and 2 (CYP2B6-rs3745274-CYP2B6-rs2279343), that 43.5% of the participants carried the heterozygous profile GT/AG, followed by the bearers of the homozygous wild-type profile GG/AA with 37.3% and 11.5% harboring the homozygous mutant TT/GG profile. The most frequent combinations in genotypes 1 and 3 (CYP2B6-rs3745274-CYP3A4-rs2740574) were represented by GT/CC (homozygous/homozygous wild-type) with 26.8%, GG/CC (both homozygous wild-type) with 25.4%, GT/CT (both heterozygous) with 17.2% and GG/CT (homozygous wild-type/heterozygous) with 11%, respectively. Compared to this, a similar pattern of inheritance of the combined genotypes was observed in genotypes 2 and 3 (CYP2B6-rs2279343-CYP3A4-rs2740574) with 26.8% of subjects harboring AG/CC, 23.9% for AA/CC, 19.1% for AG/CT, and 11% for AA/CT. In terms of the combination of the three genotypes, we observed that 24.9% of our participants simultaneously inherited the GT/AG/CC genotypes, followed by GG/AA/CC with 23.9%, GT/AG/CT with 16.7%, and GG/AA/CT with 10%. Of the 209 participants, the triple genotype frequencies associated with impaired enzymatic activities were 5.3% for subjects harboring the TT/GG/CT profile, 4.3% for TT/GG/CC, and 1.9% for TT/GG/TT.

4. Discussion

One of the major challenges of the twenty-first century for researchers and clinicians is to be able to predict the therapeutic outcomes of an individual for a given drug on the one hand and, on the other hand, to understand the development of multifactorial diseases. CYP450 is well known to be involved in the metabolism of many drugs as well as in the development of multifactorial diseases. This is the first time that the distribution of CYP2B6-rs3745274, CYP2B6-rs2279343 and CYP3A4-rs2740574 has been established in Malian healthy subjects. The frequency of the CYP2B6-rs3745274 mutant T allele observed in the Malian population was 37%, which is comparable to those observed in Central Africa (Cameroon 37%),[24] East Africa (Tanzania) 34%,[26] South Africa 36%[26] and in West African countries including Ivory Coast (38%),[27] Nigeria (36.3%),[28] and Ghana (46%).[29,30] Looking at data

---

**Table 1**

| Genes/SNPs | Genotypes/Alleles | All Participants, N (%) | Male, N (%) | Female, N (%) | P |
|------------|-------------------|-------------------------|-------------|---------------|---|
| CYP2B6∗6/rs3745274 | GG | 83 (40) | 40 (45) | 43 (36) | .32 |
| | GT | 96 (46) | 39 (44) | 57 (48) | .17 |
| | TT | 30 (14) | 10 (11) | 20 (17) | .85 |
| | G | 262 (63) | 119 (67) | 143 (60) | .88 |
| | T | 156 (37) | 59 (33) | 97 (40) | .77 |
| HWE: P | .77 | 1 | .85 |

| CYP2B6∗4/rs2279343 | AA | 80 (38) | 39 (44) | 41 (34) | .32 |
| | AG | 100 (48) | 40 (45) | 60 (50) | .32 |
| | GG | 29 (14) | 10 (11) | 19 (16) | .32 |
| | A | 260 (62) | 118 (66) | 142 (59) | .32 |
| | G | 158 (38) | 60 (34) | 98 (41) | .32 |
| HWE: P | .88 | 1 | .85 |

| CYP3A4/rs2740574 | CC | 120 (57) | 49 (55) | 71 (59) | .83 |
| | CT | 74 (35) | 33 (37) | 41 (34) | .83 |
| | TT | 15 (7) | 7 (8) | 8 (7) | .83 |
| | C | 314 (75) | 131 (74) | 183 (76) | .83 |
| | T | 104 (25) | 47 (26) | 57 (24) | .83 |
| HWE: P | .46 | .78 | .61 |

*Χ²=2.27.  
†Χ²=2.3.  
‡Χ²=0.37.  

---

![Figure 1. Haplotypes distribution of CYP2B6-rs3745274 and CYP2B6-rs2279343 in the Malian population.](image-url)
from North Africa, we found that the frequency observed in Mali was statistically higher than that reported in Egypt (28.8%) \( P = .03 \), but lower than that observed in the Moroccan population (55.5%) \( P = .000 \). As for CYP2B6-rs2279343, the frequency of the mutant G allele was 38% in the Malian population. This frequency was almost comparable to the frequencies reported in other African countries such as Egypt (30.4%), Cameroon (35%), and South of Africa (36%) (Table 2). The frequencies of CYP2B6 in exons 4 and 5 reported in the European and Asian population were slightly lower than those observed in Mali.\(^{[26]}\) Overall, the minor allele frequencies for both CYP2B6-rs3745274 and CYP2B6-rs2279343 observed in Mali were similar to the frequencies reported in the 1000 Genomes project for the African population.\(^{[32]}\) We noted a high LD between the two SNPs in CYP2B6 gene, showing their proximity. The frequencies of haplotypes in the Malian population were comparable to those observed in Cameroon and South African.\(^{[26]}\)

It has been reported that the CYP2B6-rs2279343 variant is associated with an increase protein expression with strong enzymatic activity, and that the opposite effect is observed with the CYP2B6-rs3745274 variant.\(^{[31,33]}\) In our analysis, we noticed in genotypic combination 1;2 that approximately 43.5% of our participants carried heterozygous genotypes while subjects harboring normal and mutated homozygous genotypes were 37.3% and 11.5%, respectively.

These results could suggest a compensatory effect between these two SNPs which also exhibit strong linkage disequilibrium. The involvement of these SNPs of CYP2B6 gene in the metabolism of various drugs has been demonstrated by several studies.\(^{[14,34]}\) Efavirenz and nevirapine (two non-nucleotide reverse transcriptase inhibitors) are among the flagship drugs whose metabolism is influenced by CYP2B6 SNPs. In fact, the association between high plasma concentrations of drugs leading to side effects on the central nervous system and the presence of the CYP2B6 rs3745274 polymorphism has been reported in HIV patients receiving efavirenz, while the CYP2B6 rs2279343 polymorphism has been found to be associated with increased metabolic activities with low plasma exposure.\(^{[22]}\) Thus, the genotyping of these SNPs in our HIV-positive patients could allow better therapeutic management while limiting the occurrence of central nervous system related side effects. In addition, the drugs prescribed to treat cases of malaria are currently artemisinin-based combinations and these are metabolized by CYP2B6 genes. Carriers of CYP2B6-rs3745274 variant have been reported to undergo a drug interaction when efavirenz and lumefantrine are co-administered, resulting in decreased plasma lumefantrine concentrations. AIDS and malaria are common in Mali; therefore, establishing the genetic profile of CYP2B6 in our HIV patients infected with malaria parasite will facilitate better classification of patient according to their genotypes and

| Genotypes 1:2 | N (%) |
|---------------|-------|
| GT/AG         | 91 (43.5) |
| GG/AA         | 78 (37.3) |
| TT/GG         | 24 (11.5) |
| TT/AG         | 6 (2.9) |
| GG/AG         | 3 (1.4) |
| GT/GG         | 3 (1.4) |
| GG/GG         | 2 (1) |
| GT/AA         | 2 (1) |

| Genotypes 1:3 | N (%) |
|---------------|-------|
| GT/CC         | 56 (26.8) |
| GG/CC         | 53 (25.4) |
| GT/CT         | 36 (17.2) |
| GG/CT         | 23 (11) |
| TT/CT         | 15 (7.2) |
| TT/CC         | 11 (5.3) |
| GO/TT         | 7 (3.3) |
| GT/TT         | 4 (1.9) |
| TT/TT         | 4 (1.9) |

| Genotypes 2:3 | N (%) |
|---------------|-------|
| AG/CC         | 56 (26.8) |
| AA/CC         | 50 (23.9) |
| AG/CT         | 40 (19.1) |
| AA/CT         | 23 (11) |
| GG/CC         | 14 (6.7) |
| GG/CT         | 11 (5.3) |
| AA/TT         | 7 (3.3) |
| AG/TT         | 4 (1.9) |
| GG/TT         | 4 (1.9) |

| Genotypes 1:2:3 | N (%) |
|-----------------|-------|
| GTAGCC          | 52 (24.9) |
| GGAACT          | 50 (23.9) |
| GTAGCT          | 35 (16.7) |
| GGACCT          | 21 (10) |
| TTGGCT          | 11 (5.3) |
| TTGGCC          | 9 (4.3) |
| GGAATT          | 7 (3.3) |
| GTAGCTT         | 4 (1.9) |
| TTAGCT          | 4 (1.9) |
| TTGGCTT         | 4 (1.9) |
| GTGGCC          | 3 (1.9) |
| GGAGCC          | 2 (1) |
| TGGGCC          | 2 (1) |
| TTAGCC          | 2 (1) |
| GGAGCT          | 1 (0.5) |
| GTAACC          | 1 (0.5) |
| GTAACCT         | 1 (0.5) |

Figure 2. Distribution of combined genotypes between CYP2B6-rs3745274, CYP2B6-rs2279343 and CYP3A4-rs2740574.
alternative use of others antimalarials drugs. The frequency of CYP3A4 rs2740574 alleles observed in the Malian population (75%) was comparable to those reported in Ghana 80.5%,[35] Senegal 78.3%,[35] Cameroon 78%,[26] Tanzania (74%),[29] South Africa (66%),[26] but significantly higher than those reported in North African Countries, including Morocco (24.4%),[36] Algeria (16.9%),[37] Tunisia (10.8%),[36] and Libya (19.9%)[37] (Table 2). The frequency of CYP3A4 rs2740574 is almost less than 5% in Europe and Asia, but more than 65% in populations of black African origin.[32] The impact of CYP3A4 rs2740574 polymorphism on gene expression remains controversial when we review the data in the literature. However, some authors have reported that this SNP influences the metabolism of antimalarial drugs such as artemisinin combination and quinine.[29,30] It has been reported that due to the reduced binding of a transcriptional repressor, the CYP3A4 rs2740574 variant leads to an increase in enzyme expression.[38] However, a study in pregnant women from Tanzania reported that this variant was associated with decreased enzyme activity and that the clinical and parasitological therapeutic responses were comparable between homozygous wild-type and mutated carriers.[39] Therefore, the identifying of the CYP3A4 rs2740574 variant will better guide the evidence-based prescription of this drug.

5. Conclusion

In the present study, we identified the genetic profiles of CYP2B6 rs3745274, CYP2B6 rs2279343 and CYP3A4 rs2740574 in a sample of the Malian population. The results obtained provide new insights on the distribution of drug metabolizing enzymes in the Malian population not described previously. In addition, they will contribute to the implementation of pharmacogenetic studies on drugs, which are substrates of these genes, in particular antiretrovirals and antimalarials for better genotype–phenotype correlation.

Acknowledgments

The authors would like to express special thanks to the study participants; the university clinical research center (UCRC-Mali); Prof Cheick Fantamady Traore, Prof Mahamadou Diakite and Dr Mamadou Coulibaly for logistical support.

Author contributions

Conceptualization: Yaya Kassogue, Brehima Diakite.
Data curation: Yaya Kassogue, Oumar Kassogue, Issa Konate, Kadiatou Tamboura.
Formal analysis: Yaya Kassogue, Brehima Diakite.
Funding acquisition: Yaya Kassogue.
Investigation: Brehima Diakite, Konate Issa, Kadiatou Tamboura, Zoumana Diarra, Mamoudou Maiga, Sounkalo Dao.
Methodology: Yaya Kassogue, Brehima Diakite, Oumar Kassogue, Guimogo Dolo.
Supervision: Hind Dehbi, Sylalla Nadiif, Cheick Bougadar Traore, Bakarou Kamate, Sounkalo Dao, Seydou Doumbia, Guimogo Dolo.
Validation: Yaya Kassogue.
Writing – original draft: Yaya Kassogue.
Writing – review & editing: Yaya Kassogue, Brehima Diakite.

Table 2

| Populations       | N   | rs3745274T (%) | rs2279343G (%) | rs2740574C (%) | References |
|-------------------|-----|---------------|---------------|---------------|------------|
| West Africa       |     |               |               |               |            |
| Malian (this study) | 209 | 37            | 38            | 75            | Present study |
| Ivory Coast       | 41  | 38            | –             | –             | [27]        |
| Nigeria           | 150 | 36.3          | –             | –             | [24]        |
| Ghana             | 80/118 | 48.8         | 47.5          | 80.5          | [35,42]     |
| Senegal           | 173 | –             | –             | 78.3          | [35]        |
| North Africa      |     |               |               |               |            |
| Egypt             | 120 | 28.8∗         | 30.4          | –             | [43]        |
| Morocco           | 64  | 55.5∗         | –             | 24.4∗         | [15,36]     |
| Algeria           | 83  | –             | –             | 16.9          | [37]        |
| Tunisia           | 102 | –             | –             | 10.8          | [36]        |
| Libya             | 93  | –             | –             | 19.9          | [37]        |
| Central Africa    |     |               |               |               |            |
| Cameroon          | 69  | 37            | 35            | 78            | [26]        |
| East Africa       |     |               |               |               |            |
| Tanzania          | 134/121 | 34         | –             | 74            | [29]        |
| Ethiopia          | 264 | 31.4          | –             | –             | [44]        |
| South Africa      |     |               |               |               |            |
| South Africa      | 153 | 36            | 36            | 66            | [26]        |
| Zimbabwe          | 118 | 45            | –             | –             | [27]        |

∗ statistically significant when compared to Malian.
References

[1] Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets 2017;19:38–54.

[2] Pikuleva IA. Cytochrome P450s and cholesterol homeostasis. Pharmacol Ther 2006;112:761–73.

[3] Durairaj P, Fan L, Du W, Ahmad S, Mebrahtu D, Sharma S, et al. Functional expression and activity screening of all human cytochrome P450 enzymes in fission yeast. FEBS Lett 2019;593:1372–80.

[4] Xie F, Ding X, Zhang QY. An update on the role of intestinal cytochrome P450 enzymes in drug disposition. Acta Pharm Sin B 2016;6:374–83.

[5] Purnapatre K, Khattar SK, Saini KS. Cytochrome P450s in the development of target-based anticancer drugs. Cancer Lett 2008;259:1–15.

[6] Oostendorp RL, Marchetti S, Beijnen JH, Mazzanti R, Schellem JHM. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. Cancer Chemother Pharmacol 2007;59:855–60.

[7] Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879–94.

[8] Van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, et al. Platinum-based combinations. Malar J 2014;13:2103.

[9] Ali GT, Al-azhary NM, Mokhtar DA. Frequency and prognostic effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008;64:377–65.

[10] Lee YH. Assessing the causal association between smoking behavior and CYP3A4 genetic polymorphism on the pharmacokinetics of tacrolimus in adult renal transplant recipients: a meta-analysis. PLoS One 2013;8:41–9.

[11] Swart M, Skelton M, Wonkam A, Kannemeyer L, Chin’ombe N, Dandara C. CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 polymorphisms in two Bantu-speaking populations from Cameroon and South Africa: implications for global pharmacogenetics. PCPM 2012;10:43–53.

[12] Rajeev KM, Mark NZ, Peter AZ. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 2006;62:267–75.

[13] Toyin A.S. ad , Olugbenga SJ, Ayodele BR, Joseph OO, Moji BOT. Allele and genotype frequencies of cytochrome P450 2B6 rs37452747 > T single nucleotide polymorphism in HIV-negative and HIV-infected adult Nigerian populations. Am J Transplant 2016;23:1715–9.

[14] Hodel EMS, Csajka C, Arvey F, Guidi M, Kabanywanyi AM, Duong S, et al. Effect of single nucleotide polymorphisms in cytochrome P450 soxenyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother 2013;57:950–8.

[15] Pikuleva IA. Cytochrome P450s and cholesterol homeostasis. Pharmacol Ther 2006;59:400–41.

[16] Rajeev KM, Mark NZ, Peter AZ. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 2006;62:267–75.

[17] Van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, et al. Platinum-based combinations. Malar J 2014;13:2103.

[18] The International Genome Consortium. www.1000Genomes.org.

[19] Ariyoshi N, Ohara M, Kaneko M, Afuso S, Kumamoto T, Nakamura H, et al. Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262. Drug Metab Dispos 2011;39:2045–8.

[20] Marwa KJ, Schmidt T, Sjögren M, Minzi O, Kamuhabwa AAR, Homann MV, et al. Effect of pharmacogenetics on plasma CYP3A4 and sulfotransferase gene variation in north African populations. Pharmaco- genomics 2016;17:1415–23.

[21] Mieli-Vergani G. Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. Malar J 2014;13:1–7.

[22] Zeigler-Johnson CM, Walker AH, Manzke B, Spangler E, Jalloh M, McBride S, et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SDR5A2 and CYP3A4. Human Hered 2002;54:13–21.

[23] Novillo A, Romero-Lorca A, Gaibor M, Bahri R, Hariach N, Sánchez-Cuenca D, et al. Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia. J Biol Mar Sci 2008;30:148–51.

[24] Mcgraw J, Waller D. Cytochrome P450 variants in different ethnic populations. Expert Opin Drug Metab Toxicol 2012;8:371–82.

[25] Solé X, Guiné E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006;22:1928–9.

[26] Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, et al. CYP2B6 Arg262Cys polymorphism and possible implications for anti-HIV therapy with efavirenz. J Acquir Immune Defic Syndr 2011;57:13–20.

[27] Hoffman SMG, Nelson DR, Keeney DS. Organization, structure and evolution of the CYP2 gene cluster on human chromosone 19. Pharmacogenetics 2001;11:687–98.

[28] Rengarajan C, Shankar L, Balamurugan P, Bhattacharyya S, et al. Comparative study of different haplotype blocks among the Indian population. Cytogenet Genome Res 2007;118:101–5.

[29] Shah M, Bhatia S, Goel A, Shrivastava R, et al. Cytochrome P450 2B6 gene polymorphism in 124 patients with lower gastrointestinal cancers. Pharmacogenomics 2014;15:1423–35.

[30] Vyas M, Kohli NK, Kumar S, Mahesh SJ, et al. Association of cytochrome P450 genetic polymorphisms with CYP3A4, CYP2C19, and CYP2C9 in breast cancer patients. J Immunol Res 2016;2016:73.

[31] Kassogué P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets 2017;19:38–54.

[32] Pikuleva IA. Cytochrome P450s and cholesterol homeostasis. Pharmacol Ther 2006;112:761–73.

[33] Durairaj P, Fan L, Du W, Ahmad S, Mebrahtu D, Sharma S, et al. Functional expression and activity screening of all human cytochrome P450 enzymes in fission yeast. FEBS Lett 2019;593:1372–80.

[34] Xie F, Ding X, Zhang QY. An update on the role of intestinal cytochrome P450 enzymes in drug disposition. Acta Pharm Sin B 2016;6:374–83.

[35] Purnapatre K, Khattar SK, Saini KS. Cytochrome P450s in the development of target-based anticancer drugs. Cancer Lett 2008;259:1–15.

[36] Oostendorp RL, Marchetti S, Beijnen JH, Mazzanti R, Schellem JHM. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. Cancer Chemother Pharmacol 2007;59:855–60.

[37] Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879–94.

[38] Van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, et al. Influence of CYP3A4 inhibition on the steady-state pharmacoki- netics of imatinib. Clin Cancer Res 2007;13:3794–400.

[39] Nelson DR. Gene nomenclature by default, or BLASTing to Babel. Hum Genom 2005;2:196–201.

[40] Lee YH. Assessing the causal association between smoking behavior and risk of gout using a Mendelian randomization study. Clin Rheumatol 2018;37:1099–105.

[41] Ali GT, Al-azhary NM, Mokhtar DA. Frequency and prognostic effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008;64:377–65.

[42] Perazuk SR, Kabuye G, Muyengyi P, Mhamunya F, Natarajan V, Alfaro RM, et al. Cytochrome P450 2B6 (CYP2B6) Gen37452747T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Medicine 2007;8:86–91.

[43] Reay R, Dandara C, Viljoen M, Rheeders M. CYP2B6 haplotype predicts efavirenz plasma concentration in black South African HIV-1-infected children: a longitudinal pediatric pharmacogenomic study. OMICS 2012;16:465–71.

[44] Shi WL, Tang HL, Zhai S, Di. Effects of the CYP3A4 6 1B genetic of cytochrome P450s on the pharmacokinetics of tacrolimus in adult renal transplant recipients: a meta-analysis. PLoS One 2015;10:1–14.